Novartis CEO Vas Narasimhan says that Europe needs a “complete rethink” on how it prices its drugs, warning that the entrance ...
Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...
Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker ...
When it comes to matching the commercial scale-up to the innovations taking place across Kite’s pipeline, Alquist admitted ...
Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher (PRV), striking a $180 ...
After breaking through the blockbuster sales threshold in 2025, AstraZeneca’s three-in-one inhaler Breztri Aerosphere has ...
Haleon has kicked off a soccer-focused marketing campaign ahead of the Fifa World Cup coming to the U.S., putting midfielder ...
Novartis CEO Vas Narasimhan is doubling down on his $5 billion peak sales projection for Pluvicto, even as the company has ...
GSK’s Tesaro unit took a blow in its legal feud with Jemperli developer AnaptysBio, with a Delaware court dismissing GSK’s ...
Mundipharma and CorMedix have unveiled a win for their antifungal drug Rezzayo at preventing invasive fungal diseases in ...
With Xtandi's growth days numbered, an unfazed Astellas expects a group of new products will more than offset the decline of ...
As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results